Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases.

Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, de Wilde RF, Brosens LA, Rezaee N, Javed A, Gobbo S, Regi P, Salvia R, Bassi C, He J, Weiss MJ, Cameron JL, Offerhaus GJA, Hruban RH, Lawlor RT, Scarpa A, Heaphy CM, Wood LD, Wolfgang CL.

Ann Surg. 2018 Oct 17. doi: 10.1097/SLA.0000000000003022. [Epub ahead of print]

PMID:
30339629
2.

Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.

Singhi AD, Liu TC, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, Tsung A, Marsh JW, Lee KK, Hogg ME, Bahary N, Brand RE, McGrath KM, Slivka A, Cressman KL, Fuhrer K, O'Sullivan RJ.

Clin Cancer Res. 2017 Jan 15;23(2):600-609. doi: 10.1158/1078-0432.CCR-16-1113. Epub 2016 Jul 12.

3.

Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK, Yu E, Kim SC, Hruban RH, Heaphy CM, Hong SM.

Clin Cancer Res. 2017 Mar 15;23(6):1598-1606. doi: 10.1158/1078-0432.CCR-16-1147. Epub 2016 Sep 23.

4.

Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.

VandenBussche CJ, Allison DB, Graham MK, Charu V, Lennon AM, Wolfgang CL, Hruban RH, Heaphy CM.

Cancer Cytopathol. 2017 Jul;125(7):544-551. doi: 10.1002/cncy.21857. Epub 2017 Apr 3.

5.

Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.

de Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH, Wolfgang CL, Ellison TA, Schulick RD, Molenaar IQ, Valk GD, Vriens MR, Borel Rinkes IH, Offerhaus GJ, Hruban RH, Matsukuma KE.

Mod Pathol. 2012 Jul;25(7):1033-9. doi: 10.1038/modpathol.2012.53. Epub 2012 May 11.

6.

Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.

Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ, Perren A.

Gastroenterology. 2014 Feb;146(2):453-60.e5. doi: 10.1053/j.gastro.2013.10.020. Epub 2013 Oct 19.

PMID:
24148618
7.

Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.

Roy S, LaFramboise WA, Liu TC, Cao D, Luvison A, Miller C, Lyons MA, O'Sullivan RJ, Zureikat AH, Hogg ME, Tsung A, Lee KK, Bahary N, Brand RE, Chennat JS, Fasanella KE, McGrath K, Nikiforova MN, Papachristou GI, Slivka A, Zeh HJ, Singhi AD.

Gastroenterology. 2018 Jun;154(8):2060-2063.e8. doi: 10.1053/j.gastro.2018.02.026. Epub 2018 Mar 2.

8.

CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors.

McGovern JM, Singhi AD, Borhani AA, Furlan A, McGrath KM, Zeh HJ 3rd, Bahary N, Dasyam AK.

AJR Am J Roentgenol. 2018 Nov;211(5):1020-1025. doi: 10.2214/AJR.17.19490. Epub 2018 Aug 30.

PMID:
30160983
9.

Performance of DAXX Immunohistochemistry as a Screen for DAXX Mutations in Pancreatic Neuroendocrine Tumors.

Hechtman JF, Klimstra DS, Nanjangud G, Frosina D, Shia J, Jungbluth AA.

Pancreas. 2019 Mar;48(3):396-399. doi: 10.1097/MPA.0000000000001256.

PMID:
30747827
10.

Hypo-methylation mediates chromosomal instability in pancreatic NET.

Marinoni I, Wiederkeher A, Wiedmer T, Pantasis S, Di Domenico A, Frank R, Vassella E, Schmitt A, Perren A.

Endocr Relat Cancer. 2017 Mar;24(3):137-146. doi: 10.1530/ERC-16-0554. Epub 2017 Jan 23.

11.

DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.

Park JK, Paik WH, Lee K, Ryu JK, Lee SH, Kim YT.

Oncotarget. 2017 Jul 25;8(30):49796-49806. doi: 10.18632/oncotarget.17964.

12.

Altered telomeres in tumors with ATRX and DAXX mutations.

Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK.

Science. 2011 Jul 22;333(6041):425. doi: 10.1126/science.1207313. Epub 2011 Jun 30.

13.

Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors.

Yadav R, Kakkar A, Sharma A, Malik PS, Sharma MC.

Scand J Gastroenterol. 2016 Aug;51(8):994-9. doi: 10.3109/00365521.2016.1170195. Epub 2016 May 10.

PMID:
27162024
14.

Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system.

Hong X, Qiao S, Li F, Wang W, Jiang R, Wu H, Chen H, Liu L, Peng J, Wang J, Jia C, Liang X, Dai H, Jiang J, Zhang T, Liao Q, Dai M, Cong L, Han X, Guo D, Liang Z, Li D, Zheng Z, Ye C, Li S, Zhao Y, Wu K, Wu W.

Gut. 2019 Aug 28. pii: gutjnl-2018-317233. doi: 10.1136/gutjnl-2018-317233. [Epub ahead of print]

15.

Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.

Hackeng WM, Brosens LA, Poruk KE, Noë M, Hosoda W, Poling JS, Rizzo A, Campbell-Thompson M, Atkinson MA, Konukiewitz B, Klöppel G, Heaphy CM, Meeker AK, Wood LD.

Hum Pathol. 2016 Oct;56:93-100. doi: 10.1016/j.humpath.2016.06.006. Epub 2016 Jun 21.

PMID:
27342911
16.

Neuroendocrine tumors of the pancreas: current concepts and controversies.

Reid MD, Balci S, Saka B, Adsay NV.

Endocr Pathol. 2014 Mar;25(1):65-79. doi: 10.1007/s12022-013-9295-2. Review.

PMID:
24430597
17.

ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.

Chou A, Itchins M, de Reuver PR, Arena J, Clarkson A, Sheen A, Sioson L, Cheung V, Perren A, Nahm C, Mittal A, Samra JS, Pajic M, Gill AJ.

Hum Pathol. 2018 Dec;82:249-257. doi: 10.1016/j.humpath.2018.07.032. Epub 2018 Aug 3.

18.

Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability.

Raj N, Shah R, Stadler Z, Mukherjee S, Chou J, Untch B, Li J, Kelly V, Saltz LB, Mandelker D, Ladanyi M, Berger MF, Klimstra DS, Reidy-Lagunes D, Osoba M.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00267. Epub 2018 Apr 19.

19.

The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.

Scarpa A.

Ann Endocrinol (Paris). 2019 Jun;80(3):153-158. doi: 10.1016/j.ando.2019.04.010. Epub 2019 Apr 11.

20.

Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.

Assi HA, Mukherjee S, Kunz PL, Machiorlatti M, Vesely S, Pareek V, Hatoum H.

Oncologist. 2019 Oct 2. pii: theoncologist.2019-0466. doi: 10.1634/theoncologist.2019-0466. [Epub ahead of print]

PMID:
31578277

Supplemental Content

Support Center